Atea Pharmaceuticals: Potential Best-In-Class HCV Cure With Pivotal Readouts In 2026 [Seeking Alpha]
Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus [Yahoo! Finance]
Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
Atea Pharmaceuticals (NASDAQ:AVIR) was upgraded by analysts at Evercore ISI to a "strong-buy" rating.
Atea Pharmaceuticals Inc (AVIR) Q3 2025 Earnings Call Highlights: Strategic Advances in HCV ... [Yahoo! Finance]